The objective of this study was to investigate the effects of Clostridium butyricum capsules combined
with rosuvastatin on the intestinal flora, lipid metabolism, liver function and inflammation in patients
with nonalcoholic fatty liver disease (NAFLD). For this purpose, a total of 96 patients with NAFLD
were selected as research subjects and randomly divided into a control group (n=48) and an observation
group (n=48). The Control group was treated with rosuvastatin, based on which observation group
received Clostridium butyricum capsule treatment. The efficacy in the two groups of patients was
compared, and the intestinal flora, lipid metabolism, liver function and inflammation were observed.
Results showed that the efficacy in the observation group was significantly better than that in the control
group (p<0.05). After treatment, the content of Eubacterium rectale in the observation group was lower
than that in the control group, while the content of Bacteroides thetaiotaomicron and Bifidobacteria was
notably higher than that in the control group (p<0.05). Moreover, the observation group had remarkably
lower levels of total cholesterol (TC), triglyceride (TG), free fatty acids (FFA), total bilirubin (TBIL),
direct bilirubin (DBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), procollagen
III peptide (PIIIP), collagen-IV (C-IV), hyaluronicacid (HA) and laminin (LN) as well as lower levels of
tumor necrosis factor-alpha (TNF-α), catabolite activator protein (CAP) and interleukin-6 (IL-6) in
serum than the control group (p<0.05). It was concluded that Clostridium butyricum capsules combined
with rosuvastatin can effectively improve intestinal flora imbalance, reduce blood lipid levels, and
alleviate liver fibrosis and liver function damage in the treatment of NAFLD, so it is of therapeutic
value.
